Skip to main content
. 2021 Feb 8;315(2):2057–2088. doi: 10.1007/s10479-021-03961-0

Table 2.

Optimal flow of Tetracycline to pharmacies (t = 1, 2, 3)

Brand Pharmacy No competition Competitive market
Product flow in each period Product flow in each period
1 2 3 1 2 3
Plavix 1 540 700 845 1115
2 400 510 535 640
3 900 910 900 955
4 350 300 310 200 185 175
5 290 300 295 175 184 184
6 210 210 210 180 185 180
7 350 450 284 480 614 400
Osvah 1 530 800 225 385
2 400 510 264 380
3 905 995 905 950
4 350 335 310 500 455 445
5 290 295 300 405 415 415
6 210 215 210 240 240 240
7 335 500 300 197 335 184
HHS Vulnerability Disclosure